Personalised and precision medicine
5 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- STICHTING AMSTERDAM UMC
Major Dutch academic medical center leading European research in cancer biomarkers, neurodegeneration, precision medicine, and advanced clinical imaging.
“PRECeDI (personalised chronic disease prevention), RHAPSODY (diabetes risk), BD2Decide (personalised decision support), and broad 'personalised medicine' keyword presence across the portfolio.”
PrimaryNL144 projects - INSTITUTO DE SALUD CARLOS III
Spain's national health research institute and funding agency, coordinating transnational ERA-NET calls across biomedical and public health domains.
“Coordinated ERA PerMed; participated in ICPerMed Secretariat and ERACoSysMed, covering alignment of personalised medicine funding and systems biology implementation.”
ES53 projects - FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Córdoba-based biomedical research foundation specialising in antimicrobial resistance, precision medicine, and clinical infectious disease research across European consortia.
“Coordinated P2Med, a MSCA-COFUND fellowship programme specifically for personalised and precision medicine training.”
PrimaryES6 projects - BGI SHENZHEN LIFE SCIENCE RESEARCH INSTITUTION
World-scale Chinese genomics institute bridging EU personalised medicine and biobank networks with industrial-volume sequencing capacity.
“IC2PerMed (2020–2023) positions BGI Research as a participant in the international personalised medicine consortium with an SDG3 (health) mandate.”
CN2 projects - JANSSEN-CILAG
French J&J pharmaceutical subsidiary contributing industry drug-development expertise to EU computational biomedicine and infectious disease consortia.
“CompBioMed (2016-2019) lists personalised and precision medicine as a lead keyword, where Janssen-Cilag contributed as a third-party industry partner to a Centre of Excellence in Computational Biomedicine.”
PrimaryFR2 projects